Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study.

Can ChenXi LuoWenhua TangHaofei GengJulia Martínez-PérezTimothy PriceLili KangHonglian LuYanling Zhang

Published in: Journal of gastrointestinal oncology (2024)

Regorafenib combined with ICIs led to numerically longer PFS and significantly prolonged OS in patients with mCRC compared to regorafenib monotherapy, especially in male patients.

Keyphrases

metastatic colorectal cancer
combination therapy
end stage renal disease
newly diagnosed
ejection fraction
open label